alopecia areata – Medxy AI

Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial

By MedXY 03/06/2026

The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alternative to systemic JAK inhibitors with sustained benefits.

Dermatology news Pediatrics

Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib

By MedXY 03/05/2026

This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.

Dermatology Pediatrics

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

By MedXY 10/24/2025

The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases after one year of treatment.

Allergy & Immunology Clinical Updates Dermatology Gastroenterology

Alopecia Areata Linked to Elevated Risk of Microscopic Colitis and Other Immune-Mediated GI Disorders: Clinical Insights

By MedXY 09/01/2025

A large retrospective cohort study identifies a significant association between alopecia areata and increased risks of microscopic colitis, celiac disease, Crohn’s disease, eosinophilic esophagitis, and ulcerative colitis, highlighting the need for gastrointestinal screening in affected patients.

Clinical Updates Dermatology news Specialties

FDA Fast-Tracks Rezpegaldesleukin for Severe Alopecia Areata: Promise for a Challenging Disease

By MedXY 07/30/2025

The FDA has granted Fast Track status to rezpegaldesleukin (REZPEG), a novel biologic targeting regulatory T cells, for severe-to-very severe alopecia areata in patients aged ≥12 years. Phase 2b trial results are anticipated in December 2025.